Rentschler Biopharma Announces Strategic Realignment of Global Operations

On January 30, 2025, Rentschler Biopharma SE, a global contract development and manufacturing organization for biopharmaceuticals, announced a strategic realignment of its global operations. This move involves withdrawing from the cell and gene therapy sector and ceasing operations in Stevenage, UK, while enhancing focus on biologics. The realignment aims to adapt to market conditions, prioritize sustainable growth, and drive innovation.

CEO Benedikt von Braunmühl stated that despite the slower growth in cell and gene therapy markets, the company will focus on areas with significant demand, ensuring sustainable value. The Stevenage-based team's contributions were acknowledged, and support will be provided to affected employees during the transition.

Recent investments include enhancements at the Laupheim headquarters and a new production line in Milford, MA, USA. These investments aim to boost production efficiency and meet the growing demand for biopharmaceuticals, marking the largest investment in the company's history.